Board of Directors
Thomas Oxley, MD, PhD
CEO and Founder
Dr. Oxley is the founder and CEO of Synchron and was part of the original team that created the Stentrode device at the University of Melbourne. He now leads the company out of their offices in New York, and also holds the position of neurointerventionalist in the department of neurosurgery at Mount Sinai Health System, after having completed an endovascular neurosurgery fellowship at Mount Sinai Hospital under Drs. J Mocco and Alejandro Berenstein. Dr. Oxley also completed residencies in both internal medicine and neurology, as well as a stroke fellowship, and holds a PhD from the University of Melbourne in neural engineering, which includes advanced MRI imaging analysis, hardware device (stent) development, and electrophysiological signal processing. Dr. Oxley established the Vascular Bionics laboratory in the University of Melbourne, which received substantial funding from the US defense organization DARPA, and is the founder of three start-up companies: SmartStent, VascuLab and Synchron. His work has been published in major journals including Nature Biotechnology and New England Journal of Medicine.
CTO and Founder
As chief technological officer and Synchron founder, Dr. Nicholas Opie was part of the original team that developed the Stentrode technology. Based out of Melbourne, Australia, Dr. Opie co-heads the Vascular Bionics Laboratory with the University of Melbourne, and has previously held the position of surgical program coordinator with Centre for Eye Research Australia (CERA). He received a dual bachelor’s degree in electrical and electronics engineering and science from Monash University and later went on to receive his PhD in electronic and electrical engineering from the University of Melbourne. His work has been published in major journals including Nature Biotechnology.
An experienced corporate leader with expertise in developing novel neurovascular solutions Martin Dieck, serves as chairman of Synchron. Previously, Dieck led Lazarus Effect Inc., a novel vascular interventional device, Nfocus Neuromedical, Inc., a developer of neurovascular intravascular devices, and Concentric Medical, Inc., which developed the first cleared thrombectomy device to treat large vessel ischemic stroke, which were acquired by Medtronic, Covidien and Stryker respectively. Dieck also serves as a chairman for Serenity Medical, a managing member for Neuro Technology Investors LLC and executive chairman for Cerebrotech Medical. He has received an MBA from the University of California, Berkley and a bachelor’s degree in biology from Willamette University.
Rahul Sharma, MBBS
Head of Business Development
Dr. Rahul Sharma is head of business development and a founding member of Synchron. Dr. Sharma also serves as an interventional cardiologist and assistant professor of medicine at Cedars-Sinai (Los Angeles), roles he began after completing an interventional cardiology fellowship with the medical center. He received degrees in medicine and surgery from Monash University.